MOTS-c vs IGF-1 LR3
Side-by-side comparison of key properties, dosing, and research.
- Summary
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
- Half-Life
- Estimated 1–2 hours
- 20–30 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 5–15 mg
- 40–80 mcg
- Frequency
- 3–5 times per week
- Once daily or split twice daily
- Key Benefits
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Direct muscle hypertrophy via IGF-1R stimulation
- Muscle hyperplasia (new fiber formation) — unique among peptides
- Rapid gains in lean muscle mass
- Accelerated recovery from training and injury
- Increased nutrient uptake by muscle cells
- Fat oxidation enhancement
- Bone density improvement
- Cartilage and connective tissue repair
- Side Effects
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Hypoglycemia (significant risk — insulin-like activity)
- Acromegaly-like effects with excessive long-term use
- Jaw and hand swelling
- Organ hypertrophy with extreme doses
- +2 more
- Stacks With
- —
- —